AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 92 min read$TLRY

Tilray (TLRY) Q1 2027 Earnings Call Transcript

Tilray (TLRY) reported Q1 2027 revenue of $257 million, up 23% YoY, with expanded gross margins. The company highlighted its global scale, leadership in cannabis, beverage, and wellness, and strategic acquisitions like BrewDog. Tilray emphasized its diversified business model, international growth, and cost reductions in key markets like Portugal and Germany.

Original reporting
finance.yahoo.com
Published Oct 9, 2026, 2:43 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 3:07 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Tilray (TLRY) Q1 2027 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$TLRYBearishMed
01

Why it matters

The Q1 earnings beat and maintained guidance reinforce Tilray's growth trajectory, potentially prompting buying interest.

02

Market read

First‑time earnings disclosure for Tilray provides fresh data for traders targeting cannabis, beverage and diversified growth stocks.

03

What to watch

Seasonality in the second half could temper near‑term gains despite Q1 strength.

Relevance 8/10Novelty 8/10Timing: post‑earnings today

Background

Tilray is a globally diversified cannabis, beverage and wellness company that recently acquired BrewDog and operates in multiple regulated markets.

Company-level read

Ticker impact

$TLRYBearishHigh confidence
Context

Tilray reported Q1 record revenue of $257 million, up 23% YoY, and maintained full‑year adjusted EBITDA guidance.

Expected impact

likely upward pressure as investors price in record revenue and steady outlook

Evidence & confidence

The transcript provides the first public disclosure of Q1 results, a material earnings event for a mid‑cap cannabis/beverage company.

Market effects

Sector

Strong Q1 performance may lift peer cannabis and beverage stocks, reinforcing sector growth narrative.

Regional

Highlights European expansion, especially Portugal and UK operations, supporting regional exposure to cannabis.

Global

Tilray's diversified model links cannabis, beverage and pharma sectors, offering cross‑sector trade ideas.

Counterpoint

What could challenge this read

If investors have already priced in the growth story, the modest guidance update may limit upside.

Key entities

  • Company
    Tilray Inc.

    US‑listed cannabis and beverage producer (ticker TLRY).

  • Company
    BrewDog

    Craft‑beer brand acquired by Tilray.

Read at source← All news

StoryTilray reports strong beverage-led Q1 growth but reaffirms outlook amid cannabis decline

Also covered by

4 outlets

Related articles

OCT 29
$TLRYMed

Jefferies raises Tilray stock price target on brewing restructuring

Jefferies raised its price target on Tilray Brands (TLRY) to $13 from $12, maintaining a Reduce rating. The stock trades at $2.67, down 80% over the past year. Tilray is restructuring its U.S. brewing operations, targeting $20 million in annual savings by 2028. The company reported $257.1 million in Q1 fiscal 2027 revenue, up 23% year-over-year, but posted a net loss of $40 million.

investing.com2 min
OCT 13
$TLRYMed

Tilray Medical Gains Approval For In-House Quality Testing At Portugal Facility

Tilray Brands (TLRY) received approval from Portugal's INFARMED for in-house quality testing at its Cantanhede facility. This allows microbiological and chemical/physical testing on-site, improving control and speeding up product release. The company expects reduced costs and faster supply to key markets like Germany and the UK. TLRY's stock closed at $3.36, down 5.08%, and was down 0.30% in premarket trading.

rttnews.com2 min
OCT 13
$TLRYMed

Tilray Brands, Inc.: Tilray Medical Strengthens Global Medical Cannabis Supply Chain with Approval to Bring Critical EU-GMP Quality Testing In-House, Accelerating Product Release Across Regulated Global Markets

Tilray Medical, a division of Tilray Brands (TLRY), received approval from Portugal's INFARMED to conduct in-house quality testing at its Cantanhede facility. This allows for faster product release and strengthens its global medical cannabis supply chain, benefiting markets like Germany and the UK. The move is expected to reduce costs and improve efficiency, supporting Tilray's position as a leading medical cannabis supplier.

finanznachrichten.de2 min
OCT 9
$TLRYLow

Should you sell your Tilray stock?

Tilray Brands (TSX:TLRY) reported fiscal Q1 2027 revenue of $257.1M and Adjusted EBITDA of $9.2M, missing analyst estimates. Cannabis revenue fell 13% year-over-year, while beverage alcohol revenue rose 82.1%. Analyst Neal Gilmer maintained a 'Hold' rating and $4.00 target, citing concerns about organic growth and cash flow.

cantechletter.com2 min